nicotinamide mononucleotide has been researched along with Disease Models, Animal in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, NA; Clark-Matott, J; Nagy, JA; Riveros, D; Rutkove, SB; Sanchez, B; Simon, DK; Taylor, R | 1 |
| Badalzadeh, R; Hosseini, L; Vafaee, MS | 1 |
| Hasegawa, K; Itoh, H; Kanda, T; Kawaguchi, T; Kusahana, E; Muraoka, H; Ono, T; Sakamaki, Y; Tokuyama, H; Wakino, S; Yasuda, I | 1 |
| Eliasberg, CD; Rodeo, SA; Zhang, X | 1 |
| Guan, YF; Kong, YY; Li, GQ; Miao, CY; Wang, P; Wei, CC | 1 |
| Abell, L; Caudal, A; Lee, CF; Nagana Gowda, GA; Tian, R | 1 |
| Jiang, WX; Lu, JT; Lu, YB; Tang, C; Wei, EQ; Wu, M; Zhang, WP; Zhang, XQ | 1 |
| Hu, X; Sakurai, T; Takata, T; Wang, X; Yang, Y | 1 |
| Kristian, T; Long, A; Owens, K; Park, JH | 1 |
| Imai, S; Mills, KF; Yoon, MJ; Yoshino, J | 1 |
| Ali, M; Flyvbjerg, A; Greenbaum, AL; Grønbaek, H; Kunjara, S; McLean, P; Sochor, M | 1 |
1 review(s) available for nicotinamide mononucleotide and Disease Models, Animal
| Article | Year |
|---|---|
Mitochondrial dysfunction and potential mitochondrial protectant treatments in tendinopathy.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apoptosis; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Humans; Mice; Mitochondria; Nicotinamide Mononucleotide; Oligopeptides; Reactive Oxygen Species; Superoxide Dismutase; Tendinopathy; Tendons; Thiones | 2021 |
10 other study(ies) available for nicotinamide mononucleotide and Disease Models, Animal
| Article | Year |
|---|---|
Altered muscle electrical tissue properties in a mouse model of premature aging.
Topics: Aging, Premature; Animals; Cell Size; Disease Models, Animal; DNA Polymerase gamma; DNA, Mitochondrial; Electric Impedance; Gene Knock-In Techniques; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Mutation; Myography; Nicotinamide Mononucleotide | 2019 |
Melatonin and Nicotinamide Mononucleotide Attenuate Myocardial Ischemia/Reperfusion Injury via Modulation of Mitochondrial Function and Hemodynamic Parameters in Aged Rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Drug Therapy, Combination; Hemodynamics; Isolated Heart Preparation; Male; Melatonin; Membrane Potential, Mitochondrial; Mitochondria, Heart; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Nicotinamide Mononucleotide; Oxidative Stress; Rats, Wistar | 2020 |
Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy.
Topics: Albuminuria; Animals; Claudin-1; Cytokines; Diabetic Nephropathies; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; Dose-Response Relationship, Drug; Epigenesis, Genetic; Glomerular Mesangium; Glycated Hemoglobin; Histones; Male; Mice; Mice, Knockout; NAD; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Nicotinamide-Nucleotide Adenylyltransferase; Podocytes; Sirtuin 1; Survival Rate; Time Factors | 2021 |
Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway.
Topics: Animals; Biomarkers; Brain Injuries; Cell Death; Cerebral Hemorrhage; Disease Models, Animal; Heme Oxygenase-1; Immunohistochemistry; Inflammation Mediators; Mice; Microglia; NAD; Neuroprotection; Neutrophil Infiltration; NF-E2-Related Factor 2; Nicotinamide Mononucleotide; Oxidative Stress; Protective Agents; Signal Transduction; Time Factors | 2017 |
Targeting NAD
Topics: Animals; Brain; Disease Models, Animal; Electron Transport Complex I; Female; Leigh Disease; Longevity; Male; Mice; Mice, Knockout; Mitochondria; Molecular Targeted Therapy; NAD; Nicotinamide Mononucleotide | 2019 |
NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Topics: Acrylamides; Acute Disease; Animals; Astrocytes; Brain; Brain Injuries; Calcium-Binding Proteins; Cell Count; Chronic Disease; Cold Temperature; Cytokines; Disease Models, Animal; Macrophages; Male; Mice, Inbred BALB C; Microfilament Proteins; Microglia; NAD; Neurons; Neuroprotective Agents; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Piperidines | 2015 |
Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Cognitive Dysfunction; Disease Models, Animal; Hippocampus; Long-Term Potentiation; Male; Maze Learning; Memory; Mitochondria; NAD; Neurons; Neuroprotective Agents; Nicotinamide Mononucleotide; Peptide Fragments; Rats; Rats, Wistar; Reactive Oxygen Species; Superoxides; Tissue Culture Techniques | 2016 |
Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia.
Topics: Animals; Brain Injuries; Brain Ischemia; Cell Death; Disease Models, Animal; Hippocampus; Male; Mice, Inbred C57BL; NAD; Niacinamide; Nicotinamide Mononucleotide | 2016 |
Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice.
Topics: Aging; Animals; Circadian Rhythm; Cytokines; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Glucose; Hypoglycemic Agents; Insulin; Lipid Metabolism; Mice; NAD; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Oxidative Stress; Sirtuin 1 | 2011 |
Effects of long-acting somatostatin analogues on adrenal growth and phosphoribosyl pyrophosphate formation in experimental diabetes.
Topics: Adrenal Glands; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Insulin; Male; Nicotinamide Mononucleotide; Nucleotides; Octreotide; Oligopeptides; Pentose Phosphate Pathway; Peptides, Cyclic; Phosphoribosyl Pyrophosphate; Rats; Rats, Wistar; Somatostatin; Streptozocin | 2012 |